Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

Abstract Background The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to re...

Full description

Bibliographic Details
Main Authors: Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl, Paul M. Sondel
Format: Article
Language:English
Published: BMJ Publishing Group 2019-03-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
KIR
HLA
Follicular lymphoma
NK cells
Rituximab
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0538-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0538-8

Similar Items